Miist Therapeutics Secures $7M to Disrupt Smoking Cessation and Migraine Treatment with Innovative Inhaler Technology
Miist, a startup founded by a 25-year-old, raised $7M for its inhaler that delivers rapid relief for smoking cessation and migraines.
Matilda
Miist Therapeutics Secures $7M to Disrupt Smoking Cessation and Migraine Treatment with Innovative Inhaler Technology
The fight against addiction and chronic pain has long been hampered by the limitations of traditional drug delivery methods. Slow-acting medications often lead to relapse and prolonged suffering. Enter Miist Therapeutics, a groundbreaking startup founded by a 25-year-old visionary, Dalton Signor. Miist is poised to revolutionize the treatment of smoking addiction and migraines with its innovative inhaler technology, promising rapid relief and improved patient outcomes. The company's recent $7 million seed funding round, led by prominent investors, signals a strong belief in Miist's potential to disrupt the healthcare landscape. The Genesis of Miist: A Personal Mission to Combat Addiction: Dalton Signor's journey began with a personal concern for the well-being of his family and peers. Witnessing the struggles of his grandmother, sister, and fellow students with smoking and vaping, he recognized the critical need for more effective smoking cessation solutions. Existing me…
